Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 1;34(4):414-422.
doi: 10.1097/MOP.0000000000001138.

Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes

Concetta Mastromauro  1 , Nella Polidori, Cosimo Giannini
Affiliations
Review

Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes

Concetta Mastromauro et al. Curr Opin Pediatr. .

Abstract

Purpose of review: The aim of this review is to present the new definition of the disease, defining the epidemiology, risk factors with a particular attention to the role of insulin resistance (IR) and to define the main treatments explored.

Recent findings: Nonalcoholic fatty liver disease (NAFLD) was previously considered a primary liver disease, but it would be more correct to consider it a component of the metabolic syndrome (MetS) in which IR might play a key role. Based on these findings, it has been recently proposed to modify the classic term of NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) that better reflects the pathophysiology of this complex disease.

Summary: Currently, no treatments approved in childhood are available, thus the only recommended approach is the prevention and correction of the known risk factors, and particularly of IR. However, further studies are needed to better clarify the pathogenetic mechanisms of NAFLD in order to establish more tailored therapies.

PubMed Disclaimer

References

    1. Valerio G, Maffeis C, Saggese G, et al. Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics. Ital J Pediatr 2018; 44:88.
    1. Lobstein T, Jackson-Leach R, Moodie LM, et al. Child and adolescent obesity: part of a bigger picture. Lancet 2015; 385:2510–2520.
    1. Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease’. Front Pediatr 2020; 8:603–654.
    1. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156:1264–1281.
    1. Zhang C, Yang M. Current options and future directions for NAFLD and NASH treatment. Int J Mol Sci 2021; 22:7571.

MeSH terms